According to the FDA, antigen tests will play a critical role in the fight against COVID-19 and like many other companies within the antibody world at large, Fusion Antibodies leveraged their antigen expertise to create multiple antigens to be used against the COVID-19 pandemic.
Our extensive antigen manufacturing capabilities means that we have been able to express high-purity antigens on a commercially viable scale – the rapid scale up production of COVID-19 antigens is critical for the development of widely available diagnostic tests. Unlike the PCR tests that are currently being used, these diagnostics will be able to confirm past infections and determine levels of immunity to COVID-19. This could be invaluable for disease modelling and public health policy, as true transmission rates and case fatality rates can be determined.
The RBD (Receptor Binding Domain) proteins created by Fusion Antibodies were tested by external partners against patient blood samples that they had previously tested against a leading certified benchmark test and our results, shown in the graph below, correlated exactly.
Dr Richard Buick, Chief Technical Officer of Fusion Antibodies, said:
“We are committed to developing the highest quality reagents to be used in the fight against COVID-19. Recent lab studies have shown that results using our antigens correlate 100% with clinical data from patients infected with SARS-CoV-2. We are using these high quality antigens to pan our human antibody library for SARS-CoV-2 neutralising antibodies, and we are delighted to now be able to make these antigens available to companies and researchers around the world to Test, Track & Trace this disease.”
Paul Kerr, CEO of Fusion Antibodies said:
“According to the FDA, antigen tests will play a critical role in the fight against COVID-19 and like many other companies within the antibody world at large, we are leveraging our antigen expertise to create multiple antigens to be used against the COVID-19 pandemic.”
COVID-19: Antigen Design and Manufacture
Sample data below from the SARS-CoV-2 RBD protein validated externally from over 100 samples in total using a commercial assay and patient +ve sera.